Royalty Report: Drugs, Fibrosis, Drug Discovery – Collection: 275290


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Fibrosis
  • Drug Discovery
  • Cancer
  • Delivery
  • Disease
  • Respiratory
  • Pharmaceuticals
  • Antibody
  • Immune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 275290

License Grant
As part of the 10-year global collaboration, Licensee gains rights to GLPG1690, Licensors Phase 3 candidate for idiopathic pulmonary fibrosis. Licensee also receives option rights for GLPG1972, a Phase 2b candidate for osteoarthritis, in the United States.  In addition, Licensee receives option rights on all of Licensors other current and future clinical programs outside of Europe.  Through this agreement, Licensee will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.
License Property
Both GLPG1690 and GLPG1972 are first-in-class compounds, candidate for idiopathic pulmonary fibrosis.
Field of Use
Idiopathic pulmonary fibrosis is a type of chronic lung disease characterized by a progressive and irreversible decline in lung function.

GLPG1972 is a Phase 2b candidate for osteoarthritis.

IPSCIO Record ID: 263060

License Grant
In this Agreement, the Licensee expanded the scope of the license agreement with the Licensor, who prior to 2015 was Parent of Licensee, for rights to develop and commercialize pulsed nitric oxide for idiopathic pulmonary fibrosis to include patients with Pulmonary Fibrosis (PH-PF).
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices, based on proprietary pulsatile nitric oxide delivery.

INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide.

Field of Use
The clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases,  expanded the scope of the license from PH-IPF to PH in patients with Pulmonary Fibrosis (PH-PF), which includes idiopathic interstitial pneumonias, chronic hypersensitivity pneumonitis, occupational and environmental lung disease, with a royalty on net sales of any commercial products for PH-PF.  Pulmonary fibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred.

IPSCIO Record ID: 286316

License Grant
This assignment by Licensor, a company owned by an officer of the Licensee, is for certain small-molecule therapeutics; PBI-1402, PBI-1101 as well as PBI-4050
License Property
This small molecule therapeutics platform, stems from the discovery of two receptors which we believe are at the core of how the body heals namely, promoting tissue regeneration and scar resolution as opposed to fibrosis. One of the lead drug candidates emerging from this platform, PBI-4050.

PBI-1402 is an orally active compound being developed to treat different types of anemia, such as CIA. PBI-1402 has a distinct mechanism of action and does not act through EPO receptor.

Field of Use
One of the lead drug candidates emerging from this platform, PBI-4050, is expected to enter pivotal phase 3 clinical trials for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

The field of use of PBI-4050 includes evaluating PBI-4050 in patients with IPF, and the benefits of plasminogen administration in reducing lung injury in a gold standard animal model of ALI/ARDS associated with acute pancreatitis, and,  PBI-4050, was granted an orphan drug designation status for the treatment of Alström Syndrome (AS) by the European Commission.  Alström Syndrome is chronically debilitating due to permanent blindness, deafness, type 2 diabetes and also life-threatening due to progressive organ failure.

Licensee has recently expanded its clinical program for PBI-1402 into the treatment of anemia in patients with myelodysplastic syndrome ('MDS'), a condition often referred to as 'pre-leukemia'.

PBI 1101 is a well-known chemical entity which has been approved worldwide for non-inflammatory applications.

IPSCIO Record ID: 44335

License Grant
The company executed an agreement with the University,  for an exclusive license to those rights the University may own in certain patents and patent applications relating to GBT440 and GBT440 analogs.
License Property
Product candidate, GBT440, is being developed as a once-daily, oral therapy for sickle cell disease, or SCD, and currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind clinical trial that we characterize as a Phase 1/2 clinical trial. GBT440 targets the underlying mechanism of red blood cell sickling, which we believe provides the potential to treat SCD rather than only its associated symptoms. In addition to GBT440 for the treatment of SCD, we are leveraging our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis, and hereditary angioedema, or HAE.
Field of Use
This Agreement pertains to the drug industry.

IPSCIO Record ID: 298918

License Grant
The Company granted Licensee an option to acquire (1) the Company’s rights to an intellectual property portfolio of materials and technology related to narrow spectrum kinase inhibitor compounds (the Licensed Product) and (2) an exclusive, worldwide, royalty bearing license to PUR1800, the Company’s inhaled iSPERSE drug delivery system as formulated with one of the kinase inhibitor compounds. The Company will conduct a clinical and chronic toxicology program beginning in 2020 focused on chronic obstructive pulmonary disease (COPD) and lung cancer interception.
License Property
The Company's product candidates are based on iSPERSEâ„¢, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

'Pulmatrix's iSPERSEâ„¢ platform has the ability to enhance the safety and efficacy profile of promising drug candidates. 'We applied the iSPERSEâ„¢ technology to RV1162/PUR1800, the lead in-licensed inhibitor and helped unlock its clinical potential by improving the product's profile from the original formulation.

Field of Use
These candidates are intended to be developed for lung cancer interception.

Licensee gains an option to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception.

IPSCIO Record ID: 304025

License Grant
The Company and University entered into an exclusive, worldwide license agreement for the use of certain patents and technology relating to avß1 compound in fibrosis indications.
License Property
avß1 is a integrins that is being developed for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC and for the treatment of liver fibrosis.

TGF-ß signaling is the central pathway by which fibrosis occurs. TGF-ß is a signaling molecule that is secreted by cells as an inactive complex and stored in the extra-cellular matrix. In healthy tissue, TGF-ß is transiently activated in response to tissue injury, resulting in collagen production and, ultimately, healing of the tissue. In fibrosis, however, TGF-ß becomes continuously activated, leading to excess collagen production, sometimes even in the absence of the initial tissue injury, which leads to thickening and stiffening of tissues. TGF-ß can be activated by a class of cell surface proteins known as integrins. In certain fibrotic diseases such as IPF and PSC, the integrins avß6 and avß1, which are normally expressed at very low levels, have been shown to be upregulated and to cause the continuous activation of TGF-ß. We believe that, by inhibiting fibrosis-specific TGF-ß activators such as avß6 and avß1, it may be possible to block abnormal TGF-ß activation in fibrotic tissues without affecting TGF-ß signaling in healthy tissues.

Field of Use
Licensee is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.  The initial focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-ß.

Fibrosis, also known as fibrotic scarring, is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue.

IPSCIO Record ID: 305717

License Grant
The Foundation awarded the Licensee to conduct a feasibility study using high throughput screening for cystic fibrosis targets. The Foundation also selected and provided support for the Company to conduct this high throughput screening with respect to the cystic fibrosis transmembrane conductance regulator (CFTR) target identified by the Foundation.

The parties have been conducting a research program aimed at identification and design of “Potentiator” and “Corrector” compounds, both of which are directed as a principal mode of therapeutic action at modulation of the biological effect of CFTR in different ways and with different anticipated results.

In 2004, the parties executed the Existing Agreement. The Existing Agreement contemplated that during the course of the research program, the Company would select either the Potentiator or the Corrector approach as its Primary Program (to which a majority of resources under the research program would be directed) and the other approach would be designated as an Alternative Program (to which the balance of resources would be directed).

This amendment is with respect to additional funding for the Potentiator Compounds.

License Property
The Foundation conducts research for new therapies.  They expedite the early stages of a drug and bridge the discovery gap between the academic institutions and the pharmaceutical industry.

The research program is aimed at identification and design of Potentiator and Corrector compounds, both of which are directed as a principal mode of therapeutic action at modulation of the biological effect of cystic fibrosis transmembrane conductance regulator (CFTR) in different ways and with different anticipated results.

Field of Use
The field of use is for the treatment of Cystic Fibrosis which is a rare genetic disease that affects the lungs, pancreas, and other organs.

Licensee is a funding company that collaborates with innovators from academic institutions, research hospitals and not-for-profits biotechnology companies to assist with drug research.

IPSCIO Record ID: 135993

License Grant
Licensor of the Netherlands entered into a Collaboration and License Agreement and Share Subscription Agreement with the Licensee.  Under the terms of the Collaboration Agreement, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing the Licensor’s proprietary bispecific technology platform. The collaboration encompasses up to 11 independent programs, including two of the Licensor’s current preclinical immuno-oncology discovery programs. For one of the current preclinical programs, Program 1, the Licensor retains the exclusive right to develop and commercialize products and product candidates in the United States, while Licensee has the exclusive right to develop and commercialize products and product candidates arising from such program outside the United States.  The Licensor has the option to co-fund development of products arising from two other programs in exchange for a share of profits in the United States, as well as the right to participate in a specified proportion of detailing activities in the United States for one of such programs. Should Program 1 fail to successfully complete IND-enabling toxicology studies, the Licensor would be granted an additional option to co-fund development of a program in exchange for a share of profits in the United States.  The Licensor retains the rights to its bispecific technology platform as well as clinical and pre-clinical candidates and future programs emerging from the Company’s platform that are outside the scope of the Collaboration Agreement.
License Property
The collaboration encompasses up to 11 independent programs, including two of the Licensor’s current preclinical immuno-oncology discovery programs, with respect to the research, discovery and development of bispecific antibodies utilizing the Licensor’s proprietary bispecific technology platform.
A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen.
Field of Use
This agreement applies to the drug development industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.